ABSTRACT
Background The impact of chronic health conditions (CHC) on serostatus post-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is unknown.
Methods We assessed serostatus post-SARS-CoV-2 vaccination among fully vaccinated adult residents of Jefferson County, Kentucky, USA from April 2021 through August 2021. Serostatus was determined by qualitative analysis of SARS-CoV-2 specific Spike IgG antibodies via enzyme-linked immunoassay (ELISA) in peripheral blood samples.
Results Of the 5,178 fully vaccinated participants, 51 were seronegative and 5,127 were seropositive. Chronic kidney disease (CKD) and autoimmune disease showed highest association with negative serostatus in fully vaccinated individuals. The absence of any CHC was strongly associated with positive serostatus. The risk of negative serostatus increased as the total number of pre-existing CHCs increased. Similarly, use of 2 or more CHC related medications was associated with seronegative status.
Conclusions Presence of any CHC, especially CKD or autoimmune disease, increased the likelihood of seronegative status among individuals who were fully vaccinated to SAR-CoV-2. This risk increased with a concurrent increase in number of comorbidities, especially with multiple medications. Absence of any CHC was protective and increased the likelihood of a positive serological response. These results will help develop appropriate guidelines for booster doses and targeted vaccination programs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported in part by the following funding sources: Louisville-Jefferson County Metro Government as a component of the Coronavirus Aid, Relief, and Economic Security (CARES) Act Centers for Disease Control and Prevention (# 75D30121C10273) James Graham Brown Foundation Owsley Brown II Family Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study and all the protocols were approved by the Institutional Review Board of the University of Louisville (IRB # 20.0393).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
alok.amraotkar{at}louisville.edu (A.R.A); rachel.keith{at}louisville.edu (R.J.K); hong.gao{at}louisville.edu (H.G); Aruni{at}Louisville.edu (A.B)
adrienne.bushau{at}louisville.edu (A.M.B); krystal.hamorsky{at}louisville.edu (K.T.H); kenneth.palmer{at}louisville.edu (K.E.P)
shesh.rai{at}louisville.edu (S.N.R)
Abstract has been shortened. Few sentences and citations added to Introduction and Discussion Results section reformatted for proper flow and individual results added. Figures and Tables incorporated inside the manuscript.
Data Availability
Primary deidentified data supporting the findings of this study are available through the corresponding author (Aruni Bhatnagar: Aruni.bhatnagar{at}louisville.edu) upon request.
